It began with Massachusetts Institute of Technology (MIT) “hackathons” and a billion-dollar inspiration.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
Med Ad News spoke with Gene Fitzpatrick, senior VP of engagement strategy for Ogilvy CommonHealth Worldwide, about the future of augmented and virtual reality in healthcare marketing.
Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.
As private practices close and the number of doctors joining rep-restricted hospital-based and integrated delivery networks of healthcare increases, pharma needs to look at the advantages of mobile marketing to “detail” these hospital-based professionals.
Researchers at the Massachusetts Institute of Technology (MIT) published research in the journal Science Advances describing yet another CRISPR improvement.
Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available
Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers.
Up to 10,000 Americans due to have hip or knee replacements will be able to funnel basic health data directly from their Apple Watches to their surgeons under a new app being tested by prosthetic limb specialist Zimmer Biomet.
The U.S. Food and Drug Administration lifted a clinical hold and accepted an Investigational New Drug Application (IND) for an experimental sickle cell disease treatment being jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
Medopad, a U.K.-based medical firm, and China-based Tencent Holdings have teamed up on a project that will attempt to harness artificial intelligence in the diagnosis of Parkinson’s disease.
Johnson & Johnson Vision, a broad-based global leader in eye health, launched a worldwide campaign to #spotlightsight in honor of World Sight Day on October 11, 2018.
Two Americans and a Briton won the 2018 Nobel Prize for Chemistry for harnessing the power of evolution to generate novel proteins.
Two antimalarial strategies have been published from Imperial College London: new compounds that prevent the malaria parasite from infecting mosquitoes and gene-edited mosquitoes that cannot reproduce, leading to population destruction.
Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.
Klick Health’s growing commercialization partner portfolio is proud of the successful exit of Circulation, one of Klick’s first incubation initiatives.
Voice search (such as Apple Siri) and voice assistants (such as Amazon ECHO “Alexa”) are on the rise, and it’s been predicted that by the end of 2020, 50% of interactions with technology will be via “conversations” with them.
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.
Lisle, Ill.-based medtech company Endotronix Inc. secured $45 million in a Series D financing round.
HBA is hosting two educational webinars in October 2018: “Increase Your Communication Confidence in Three Weeks: There’s an APP for That” and “Presenting Effectively in Any Situation”
One in three teen drivers in the U.S. text while driving, new survey data suggests, and the number may be higher in states where teens start driving at younger ages.
Researchers at the University of Texas Southwestern Medical Center used CRISPR gene editing to treat Duchenne muscular dystrophy (DMD) in dogs. Their work was published in the journal Science.
A new computer tool has been developed to predict how some cancers may respond to an investigational treatment before the drug has even been administered to a patient.
Intellia Therapeutics will host an educational briefing webinar on interference proceedings relating to CRISPR/Cas9 genome editing technology patents.
The U.S. Food and Drug Administration cleared Cleveland-based SPR Therapeutics’ SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems for controlling pain.